ResearchMoz presents this most up-to-date research on Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation. The report focuses primarily on quantitative market metrics in order to characterize the growth and evolution of the Frontier Pharma: Systemic Lupus Erythematosus.
Albany, NY -- (SBWIRE) -- 01/29/2014 -- The Systemic Lupus Erythematosus (SLE) drug market is currently under-served by non-generic, targeted therapies. Whilst the only Food and Drug Administration (FDA)-approved biologic, Benlysta (belimumab), generated sales of $111m in 2012, there is little evidence that the drug’s performance is ignificantly superior to other B-cell targeted therapies such as Rituxan (rituximab), which is often used off-license to treat refractory SLE patients. Therapeutics entering the market therefore do not face the staggering level of competition from currently marketed programs as in other markets such as the Rheumatoid Arthritis (RA) market. Emerging market entrants that appear to offer significant therapeutic benefits are likely to cause dramatic changes to the market landscape.
View Full Report With Complete TOC at http://www.researchmoz.us/frontier-pharma-systemic-lupus-erythematosus-identifying-and-commercializing-first-in-class-innovation-report.html
A growing understanding of the signaling pathways underlying SLE pathophysiology including, but not limited to, B cells, T cells and intracellular kinases, is translating into a higher number of novel, and more importantly, first-in-class targeted therapeutics entering the developmental pipeline. In particular, a high level of investment in the development of cytokine-blocking strategies is evident, as therapies targeting the interferon pathway are relatively common in the pipeline.
The report analyzes the market for SLE therapeutics and the pipeline products in that market, with particular emphasis on first-in-class programs.
A brief introduction to SLE, including symptoms, pathophysiology, disease scoring indices and overview of pharmacotherapy
In-depth analysis and literature review on marketed products, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses, based on published clinical trials, as well as a reference table of drugs in terms of safety and efficacy
Overview of how innovation products are contributing to the market for SLE therapeutics
Comprehensive review of the pipeline for first-in-class therapies, which is analyzed on the basis of phase distribution, molecule types and molecular targets, as well as administration routes
The changing molecular target landscape between market and pipeline, and, in particular, focal points of innovation
First-in-class molecular targets, highlighting early-stage programs for which clinical utility has yet to be evaluated, as well as an in-depth literature review on novel molecular targets
View All GBI Market Research Reports- http://www.researchmoz.us/publisher/gbi-research-2.html
Reasons to buy
The report will assist the business development strategies of companies that wish to develop novel therapies with improved benefits to existing treatments. It will also be of interest to companies seeking to expand their pipeline portfolio through licensing agreements and co-development deals. Primarily, the report will allow clients to identify and understand market opportunities and the emerging competitive environment. It will also allow you to
Understand the SLE pipeline and the factors which indicate that it is becoming more innovative
Understand the overall focal shifts in therapeutic molecular targets for the treatment of SLE
Understand the distribution of the pipeline programs by phase of development, molecule type and molecular target
Identify the list of first-in-class programs that are potentially open to deal-making opportunities
Understand the first-in-class developmental programs and gauge the current clinical effectiveness based on animal models
Related Reports -
Frontier Pharma - Rheumatoid Arthritis: Identifying and Commercializing First-in-Class Innovation
Frontier Pharma: Rheumatoid Arthritis Identifying and Commercializing First-in-Class Innovation”. This highly competitive market is saturated with multiple targeted monoclonal Antibody (mAb) therapies and small molecules, yet more of these treatments are expected to enter the market over the next few years. Despite this, the current developmental pipeline is highly innovative beyond these me-too products and incremental innovations and promises a number of first-in-class products across all stages. These new developments are driven by improvements in the understanding of signaling pathways and underlying disease mechanisms of Rheumatoid Arthritis (RA). These highly innovative products are expected to increase the diversity of available products, in terms of mechanism of action over the coming decade and are likely to have a significant impact on the dynamics of the clinical and commercial landscape.
View Full Report With Complete TOC at http://www.researchmoz.us/frontier-pharma-rheumatoid-arthritis-identifying-and-commercializing-first-in-class-innovation-report.html
Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019 - Strong Potential for Pipeline Biologics on Account of High Regional Unmet Need
Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019 – Strong Potential for Pipeline Biologics on Account of High Regional Unmet Need", which provides insights into three therapeutic indications in gastrointestinal disorders in Asia-Pacific (APAC) markets of India, China, Japan and Australia. The report provides an in-depth analysis of the therapeutic indications of gastrointestinal disorders, namely Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC) and Crohn’s Disease (CD). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these three gastrointestinal indications.
View Full Report - http://www.researchmoz.us/gastrointestinal-therapeutics-in-asia-pacific-markets-to-2019-strong-potential-for-pipeline-biologics-on-account-of-high-regional-unmet-need-report.html
Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth
Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth” Gastric and esophageal cancers are two orphan cancers of the gastrointestinal tract. They are often diagnosed at advanced, incurable stages due to a late onset of symptoms, but are also associated with low survival rates in the early stages of disease. Currently the primary treatment options are chemotherapy and surgery, which are used wherever possible. One monoclonal Antibody (mAb), Herceptin (trastuzumab) is marketed for use in suitable patients with advanced gastric or gastro-esophageal junction cancer. However, the late-stage pipelines for these indications include many promising mAb candidates which are anticipated to enter the market during the forecast period.
View Full Report With Complete TOC at http://www.researchmoz.us/monoclonal-antibodies-market-in-gastric-and-esophageal-cancers-to-2019-crowded-late-stage-pipelines-and-favorable-market-conditions-encourage-robust-growth-report.html
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
Browse Blog - http://latestmarketstudy.blogspot.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)